The Clorox Company
NYSE:CLXHousehold & Personal Products
-$2.54 today
- Market cap
- $13.13B
- Beta
- 0.55
- P/E (TTM)
- 15.2
- EPS (TTM)
- $6.23
- Dividend yield
- 5.22%
Volume 2.16M
Average 2.84M
CLX Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
The Clorox CompanyNYSE: CLX
Stock-Based Compensation · Q1 FY2027 · quarter ended Sep 2026
Stock-based compensation declines year over year
Q1 FY2027 stock-based compensation of $9M fell 10.0% year over year, ahead of the -39.7% change in trailing-twelve-month stock-based compensation. Over 3 fiscal years it compounded at -13.0% a year.
Context
- Stock-based compensation amounted to 0.7% of revenue in FY2026, down 0.4 pp from a year earlier.
- Stock-based compensation increased in 2 of the last 3 fiscal years.
- FY2026 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -10.0% holds above the trailing-twelve-month pace of -39.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2026
- 48M USD
- Year-over-year change
- -40.7%
- 4-year CAGR
- -2.0%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2026 | 2026-06-30 | 48M | -40.7% |
| FY2025 | 2025-06-30 | 81M | +9.5% |
| FY2024 | 2024-06-30 | 74M | +1.4% |
| FY2023 | 2023-06-30 | 73M | +40.4% |
| FY2022 | 2022-06-30 | 52M | — |
Stock-Based Compensation vs competitors
How CLX compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -39.7% is the 9th highest of 10, against a peer median of -8.4%.
- Stock-based compensation amounts to 0.7% of revenue for CLX, versus a peer median of 0.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $501M USD | +1.8% | -1.3% | 0.6% | |
| FY2025 | €255M EUR | -21.3% | +12.9% | 0.5% | |
| LTM Sep 2026 | $141M USD | -8.4% | — | 0.7% | |
| LTM Jun 2026 | $131M USD | -1.5% | -2.3% | 0.8% | |
| LTM Sep 2026 | $74.3M USD | +40.7% | +21.5% | 1.2% | |
| LTM Sep 2026 | $59M USD | -63.1% | -0.2% | 0.4% | |
| LTM Sep 2026 | $47M USD | -39.7% | -13.0% | 0.7% | |
| LTM Jun 2026 | $26.4M USD | +36.8% | +26.2% | 0.9% | |
| LTM Mar 2026 | $21.1M USD | -17.6% | +1.0% | 1.0% | |
| LTM Jun 2026 | $18M USD | -14.3% | +61.3% | 0.5% | |
| LTM Dec 2025 | $0 USD | — | — | — | |
| Peer median (excluding CLX) | — | -8.4% | +7.0% | 0.7% | |
Competitors are the stored peer set for CLX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Jun 2022 | FY2023 Jun 2023 | FY2024 Jun 2024 | FY2025 Jun 2025 | FY2026 Jun 2026 |
|---|---|---|---|---|---|
| Net Income | 471M | 161M | 292M | 824M | 601M |
| Depreciation & Amortization | 224M | 236M | 235M | 219M | 247M |
| Deferred Income Tax | 5M | (149M) | (100M) | (18M) | 81M |
| Stock-Based Compensation | 52M | 73M | 74M | 81M | 48M |
| Change in Working Capital | (99M) | 354M | (241M) | (211M) | 118M |
| Accounts Receivables | (84M) | (13M) | (34M) | (145M) | 151M |
| Inventory | (18M) | 58M | 55M | 63M | (71M) |
| Accounts Payables | (47M) | 157M | (140M) | (124M) | 38M |
| Other Working Capital | 50M | 152M | (122M) | (5M) | 0 |
| Other Non-Cash Items | 133M | 483M | 435M | 86M | (483M) |
| Operating Cash Flow | 786M | 1.16B | 695M | 981M | 612M |
| Capital Expenditures | (251M) | (228M) | (212M) | (220M) | (207M) |
| Acquisitions (Net) | 0 | 0 | 17M | 128M | (2.1B) |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 22M | 5M | 20M | (2M) | 10M |
| Investing Cash Flow | (229M) | (223M) | (175M) | (94M) | (2.3B) |
| Debt Repayment | (83M) | (188M) | (45M) | 0 | 2.57B |
| Common Stock Issued | 5M | 33M | 1M | 26M | (23M) |
| Common Stock Repurchased | (25M) | 0 | 0 | (332M) | (256M) |
| Dividends Paid | (571M) | (583M) | (595M) | (602M) | (602M) |
| Other Financing Activities | (15M) | (15M) | (16M) | (16M) | (16M) |
| Financing Cash Flow | (689M) | (753M) | (655M) | (924M) | 1.67B |
| Effect of Forex Changes | (6M) | 2M | (26M) | 2M | (2M) |
| Net Change in Cash | (138M) | 184M | (161M) | (35M) | (23M) |
| Free Cash Flow | 535M | 930M | 483M | 761M | 405M |
The Clorox Company
NYSE:CLX
Intrinsic Alpha fair value
Locked
Current Price
$108.39
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.